Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)

NCT02054351 is registered in ClinicalTrials.gov with Ganymed Pharmaceuticals GmbH as lead sponsor.

NCT NCT02054351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02054351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Lead sponsor
Ganymed Pharmaceuticals GmbH
Phase
Phase 1
Overall status
Completed
Start date
February 6, 2014
Completion date
October 28, 2015
Enrollment
42 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer